Literature DB >> 31944848

Human Papillomavirus Vaccination Schedule: Adherence Among Commercially Insured Adolescents and Young Adults in the United States, 2011-2017.

Demetria Hubbard1, Sadeep Shrestha1, Emily B Levitan1, Huifeng Yun1.   

Abstract

Objectives. To determine rates of human papillomavirus (HPV) vaccine adherence to the 2011 and 2016 Advisory Committee for Immunization Practices (ACIP) recommendations in the United States.Methods. We conducted a retrospective cohort study by using the 2011 to 2017 Marketscan data for beneficiaries aged 9 to 26 years who had at least 1 claim for HPV vaccination between January 1, 2011, and January 1, 2017. According to the 2011 ACIP recommendation, adherence is defined as 30 to 90 days between the first and second vaccination and 168 to 212 days between the first and third vaccination. According to the 2016 recommendation, preadolescents are classified as adherent if they had 2 claims of vaccination within 168 to 212 days. We calculated proportions of completion and adherence by recommendation.Results. Among patients classified under the 2011 ACIP recommendation (n = 2 164 096), 8.3% completed all 3 doses of the vaccine series. Of those who completed, 69.6% were considered adherent to the recommended schedule. Completion and adherence increased to 9.6% and 70.8%, respectively, among patients who were classified under the 2016 ACIP recommendation.Conclusions. Simpler recommendations lead to better adherence to the HPV vaccination schedule.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31944848      PMCID: PMC7002965          DOI: 10.2105/AJPH.2019.305485

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  22 in total

1.  Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices.

Authors:  Elissa Meites; Allison Kempe; Lauri E Markowitz
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-12-16       Impact factor: 17.586

2.  Human papillomavirus vaccine series completion in boys before and after recommendation for routine immunization.

Authors:  Bradley Ackerson; Rulin Hechter; Margo Sidell; Lina S Sy; Jeffrey Slezak; Chun Chao; Nilesh Patel; Hung-Fu Tseng; Steven Jacobsen
Journal:  Vaccine       Date:  2017-01-13       Impact factor: 3.641

3.  Predictors of Human Papillomavirus Vaccine Completion Among Female and Male Vaccine Initiators in Family Planning Centers.

Authors:  Hannah R Simons; Zoe D Unger; Priscilla M Lopez; Julia E Kohn
Journal:  Am J Public Health       Date:  2015-10-15       Impact factor: 9.308

4.  Completion of the human papillomavirus vaccine series among insured females between 2006 and 2009.

Authors:  Jacqueline M Hirth; Alai Tan; Gregg S Wilkinson; Abbey B Berenson
Journal:  Cancer       Date:  2012-04-27       Impact factor: 6.860

Review 5.  American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors.

Authors:  Debbie Saslow; Philip E Castle; J Thomas Cox; Diane D Davey; Mark H Einstein; Daron G Ferris; Sue J Goldie; Diane M Harper; Walter Kinney; Anna-Barbara Moscicki; Kenneth L Noller; Cosette M Wheeler; Terri Ades; Kimberly S Andrews; Mary K Doroshenk; Kelly Green Kahn; Christy Schmidt; Omar Shafey; Robert A Smith; Edward E Partridge; Francisco Garcia
Journal:  CA Cancer J Clin       Date:  2007 Jan-Feb       Impact factor: 508.702

6.  Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation.

Authors:  S L Rosenthal; T W Weiss; G D Zimet; L Ma; M B Good; M D Vichnin
Journal:  Vaccine       Date:  2010-01-05       Impact factor: 3.641

7.  Human Papillomavirus-Associated Cancers - United States, 2008-2012.

Authors:  Laura J Viens; S Jane Henley; Meg Watson; Lauri E Markowitz; Cheryll C Thomas; Trevor D Thompson; Hilda Razzaghi; Mona Saraiya
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-07-08       Impact factor: 17.586

8.  Geographic Variation in the Quality and Cost of Care for Patients with Rheumatoid Arthritis.

Authors:  Jason Shafrin; Arijit Ganguli; Yuri Sanchez Gonzalez; Jin Joo Shim; Seth A Seabury
Journal:  J Manag Care Spec Pharm       Date:  2016-12

9.  Legislative activity related to the human papillomavirus (HPV) vaccine in the United States (2006-2015): a need for evidence-based policy.

Authors:  Jessica Keim-Malpass; Emma M Mitchell; Pamela B DeGuzman; Mark H Stoler; Christine Kennedy
Journal:  Risk Manag Healthc Policy       Date:  2017-03-13

10.  Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.

Authors:  Rengaswamy Sankaranarayanan; Priya Ramesh Prabhu; Michael Pawlita; Tarik Gheit; Neerja Bhatla; Richard Muwonge; Bhagwan M Nene; Pulikottil Okuru Esmy; Smita Joshi; Usha Rani Reddy Poli; Parimal Jivarajani; Yogesh Verma; Eric Zomawia; Maqsood Siddiqi; Surendra S Shastri; Kasturi Jayant; Sylla G Malvi; Eric Lucas; Angelika Michel; Julia Butt; Janki Mohan Babu Vijayamma; Subha Sankaran; Thiraviam Pillai Rameshwari Ammal Kannan; Rintu Varghese; Uma Divate; Shila Thomas; Geeta Joshi; Martina Willhauck-Fleckenstein; Tim Waterboer; Martin Müller; Peter Sehr; Sanjay Hingmire; Alka Kriplani; Gauravi Mishra; Sharmila Pimple; Radhika Jadhav; Catherine Sauvaget; Massimo Tommasino; Madhavan Radhakrishna Pillai
Journal:  Lancet Oncol       Date:  2015-12-02       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.